High Orphan Drug Prices Persist Despite Market ...

By João L. Carapinha

May 26, 2025

The article "Rare disease drug prices remain high due to lack of competition" published on ZIN's site highlights a critical concern in the European pharmaceutical market regarding orphan drug prices—the costs associated with medications for rare d...
The Impact of MFN Pricing on the U.S. Biosimilar Market
Hepatitis Vaccine Uptake: Trends, Challenges, and the Role of Pharmacists
Biosimilars Price Competition: Impact on U.S. Pharmaceutical Pricing and Mark...
MFN Drug Pricing Targets: Lowering U.S. Drug Costs Through International Alig...
HTA Reform Analysis: Patterns and Global Trends in Health Technology Assessment
Drug Pricing Analysis: ICER’s Launch Price and Access Report Aims to En...
Trends in Anticancer Drug Pricing: Analyzing Medicare Launch Prices and Impac...
A System Dynamics Approach to Lowering Drug Prices by 30–80% in the US
EFPIA Advocates for Stronger Life Sciences in EU Multiannual Financial Framework
Evolving NICE Health Technology Evaluations: Enhancing Patient Perspectives a...
Canada Drug Agency Plan: Shaping the Future of Health Systems 2025-2030
Revolutionizing Hepatitis C Treatment: The Transformative Role of Direct-Acti...